Understanding SGLT2 Inhibitors

SGLT2 inhibitors, also known as sodium-glucose cotransporter-2 inhibitors, are a widely prescribed class of oral medications for managing type 2 diabetes. Their mechanism of action is distinct from other glucose-lowering agents: they work in the kidneys by blocking the SGLT2 protein, which normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this channel, these drugs cause glucose to be excreted in the urine, effectively lowering blood sugar levels. This process is independent of insulin secretion, making them suitable for use across various stages of diabetes, including in patients who have not achieved adequate glycemic control on other therapies.

Beyond glycemic control, SGLT2 inhibitors have demonstrated significant benefits in cardiorenal outcomes. Large cardiovascular outcome trials have shown that certain agents in this class reduce the risk of heart failure hospitalization, slow the progression of chronic kidney disease, and improve survival in patients with heart failure—even in those without diabetes. These pleiotropic effects have earned SGLT2 inhibitors a preferred status in current diabetes management guidelines, alongside metformin and GLP-1 receptor agonists.

The class includes four FDA-approved agents: canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro). While they share a common mechanism, important differences in their pharmacological profiles, approved indications, safety data, and cost can influence which one is most appropriate for an individual patient.

Mechanism of Action and Pharmacokinetics

All SGLT2 inhibitors are taken orally, but their absorption, metabolism, and elimination vary slightly. They are generally absorbed within 1–2 hours and have a half-life that supports once-daily dosing. The primary site of action is the proximal tubule of the kidney, where SGLT2 mediates reabsorption of approximately 90% of filtered glucose. By blocking it, these drugs increase urinary glucose excretion, producing a mild osmotic diuresis. This diuretic effect contributes to modest reductions in blood pressure and weight loss.

The renal elimination pathway means that patients with impaired kidney function may have reduced efficacy. For example, canagliflozin and dapagliflozin require dose adjustment or are not recommended when the estimated glomerular filtration rate (eGFR) falls below a certain threshold, whereas empagliflozin was recently approved for use in chronic kidney disease with very low eGFR (down to 20 mL/min/1.73 m²) as part of its heart failure indication. Understanding these pharmacokinetic nuances is essential for safe prescribing.

Common SGLT2 Inhibitors: A Detailed Look

Canagliflozin (Invokana)

Canagliflozin was the first SGLT2 inhibitor to gain FDA approval in 2013. It is available in 100 mg and 300 mg tablets. The CANVAS trial program established its cardiovascular safety and showed a reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or multiple risk factors. Additionally, the CREDENCE trial demonstrated that canagliflozin reduces the risk of kidney failure in patients with diabetic kidney disease. However, canagliflozin carries a higher risk of lower-limb amputations and fractures compared to other SGLT2 inhibitors, and its label includes a warning about these rare but serious events.

Dapagliflozin (Farxiga)

Dapagliflozin, approved in 2014, is available in 5 mg and 10 mg doses. The DECLARE-TIMI 58 trial showed that dapagliflozin did not significantly reduce MACE but did lower the risk of hospitalization for heart failure and slowed the progression of renal disease. Based on these outcomes, dapagliflozin received FDA approval for heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) in patients with and without type 2 diabetes. It generally has a favorable side-effect profile, with lower rates of amputations than canagliflozin. Dapagliflozin is also available in combination with saxagliptin (Qtern) and metformin (Xigduo XR).

Empagliflozin (Jardiance)

Empagliflozin, approved in 2014, comes in 10 mg and 25 mg strengths. The landmark EMPA-REG OUTCOME trial demonstrated a significant reduction in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease. Remarkably, it also showed a reduction in all-cause mortality. Subsequent trials (EMPEROR-Reduced, EMPEROR-Preserved) expanded its use to heart failure with both reduced and preserved ejection fraction, making it the first SGLT2 inhibitor granted FDA approval for heart failure across the full spectrum of ejection fraction. Empagliflozin has also been studied in chronic kidney disease (EMPA-KIDNEY), confirming renal benefit. It is considered a first-line choice for many patients, particularly those with cardiovascular or renal comorbidities.

Ertugliflozin (Steglatro)

Ertugliflozin is the newest agent, approved by the FDA in 2017. It is dosed at 5 mg and 15 mg daily. The VERTIS CV trial assessed cardiovascular outcomes and found noninferiority for MACE but no superiority. No dedicated renal or heart failure trials have been completed, though a modest benefit on heart failure hospitalization was noted. Ertugliflozin has a similar side-effect profile to other SGLT2 inhibitors but is generally considered a second-line agent within the class due to the less robust evidence for cardiorenal protection. It is available as a single agent or in combination with metformin (Steglujan) and sitagliptin (Segluromet).

Comparison of Key Features

Approved Indications

All four SGLT2 inhibitors are approved for glycemic control in type 2 diabetes as adjuncts to diet and exercise. However, the extra-glycemic indications differ:

  • Canagliflozin: Approved to reduce the risk of MACE and end-stage renal disease in patients with type 2 diabetes and established cardiovascular disease or diabetic kidney disease.
  • Dapagliflozin: Approved for heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease, regardless of diabetes status.
  • Empagliflozin: Approved for reduction of cardiovascular death in type 2 diabetes with established CVD, and for heart failure (both HFrEF and HFpEF) and chronic kidney disease, with or without diabetes.
  • Ertugliflozin: No specific cardiovascular or renal indications beyond glycemic control.

Cardiovascular Outcomes

The evidence base for cardiovascular benefits is strongest for empagliflozin, followed by canagliflozin and dapagliflozin. Empagliflozin's EMPA-REG OUTCOME trial showed a 38% relative risk reduction in cardiovascular death. Canagliflozin reduced the composite of CV death, MI, and stroke by 14%. Dapagliflozin reduced the composite of CV death or heart failure hospitalization by 17% in the DECLARE trial. Ertugliflozin has no CV superiority data and is considered cardioprotective in a neutral sense.

Renal Outcomes

All three major agents (canagliflozin, dapagliflozin, empagliflozin) have demonstrated renoprotection in large randomized trials. Canagliflozin's CREDENCE trial was specifically designed for renal endpoints and showed a 30% reduction in the primary composite of end-stage renal disease, doubling of serum creatinine, or renal death. Dapagliflozin's DAPA-CKD trial demonstrated similar renal benefit in patients with CKD, including those without diabetes. Empagliflozin's EMPA-KIDNEY trial confirmed a 28% reduction in CKD progression or cardiovascular death. Ertugliflozin lacks dedicated renal outcome trials.

Side Effects and Safety Profile

Common adverse effects across the class include genital mycotic infections (more frequent in uncircumcised men and women), urinary tract infections, polyuria, and volume depletion (especially in elderly patients or those on diuretics). Rare but serious risks include:

  • Ketoacidosis (euglycemic DKA): Can occur at lower blood glucose levels than typical DKA; requires prompt recognition.
  • Lower-limb amputations: More strongly associated with canagliflozin; the mechanism is unclear.
  • Fractures: Canagliflozin use has been linked to increased fracture risk, specifically at the metatarsals.
  • Acute kidney injury: Rare, but caution is needed in patients with hypovolemia or concurrent nephrotoxic agents.
  • Fournier's gangrene (necrotizing fasciitis of the perineum): Extremely rare but life-threatening; requires immediate surgical consultation if suspected.

Dosing and Contraindications

All agents are taken once daily. Dose adjustment for renal function is critical:

  • Canagliflozin: Max dose 300 mg; not recommended if eGFR <30 mL/min. Use 100 mg if eGFR 30–45 mL/min.
  • Dapagliflozin: Max dose 10 mg; not recommended for glycemic control if eGFR <25 mL/min, but can be used for HF/CKD at any eGFR down to 25.
  • Empagliflozin: Max dose 25 mg; can be used down to eGFR 20 mL/min for heart failure/CKD; for glycemic control, avoid if eGFR <30.
  • Ertugliflozin: Max dose 15 mg; not recommended if eGFR <30 mL/min.

Contraindications include hypersensitivity, dialysis, and severe hepatic impairment (except dapagliflozin labeled caution).

Cost and Insurance Coverage

Prices vary widely based on insurance plans and pharmacy. Brand-name drugs have list prices around $500–$600 per month, but most insurers cover at least one agent preferentially. Canagliflozin, empagliflozin, and dapagliflozin have patient assistance programs. Generic versions are not yet available in the US, but ertugliflozin may be less expensive in some formularies. It is worth exploring copay savings cards or pharmacy-specific discount programs. Note that Medicare Part D plans may require prior authorization for certain medications.

Choosing the Right SGLT2 Inhibitor for You

Selection of a specific SGLT2 inhibitor should be individualized based on the patient's clinical profile, comorbidities, and treatment goals. The following factors are key:

Cardiovascular History

For patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk, empagliflozin or canagliflozin are preferred due to robust outcome data. If heart failure is present (especially with reduced ejection fraction), empagliflozin or dapagliflozin are evidence-based choices. Dapagliflozin and empagliflozin are now also first-line for heart failure without diabetes.

Chronic Kidney Disease

If the patient has diabetic kidney disease or CKD (eGFR 25–60 mL/min with albuminuria), canagliflozin, dapagliflozin, or empagliflozin are all effective. Empagliflozin and dapagliflozin are approved down to very low eGFR for renal protection. Ertugliflozin is not recommended for renal protection due to lack of evidence.

Weight and Blood Pressure Goals

All SGLT2 inhibitors promote modest weight loss (2–3 kg on average) and reduce systolic blood pressure by 3–5 mmHg. The effect is similar across agents, though canagliflozin 300 mg may produce slightly greater weight loss. Patients who already have low blood pressure or are on multiple antihypertensives need careful monitoring for hypotension and volume depletion.

Safety Considerations

Patients with a history of recurrent genital infections may benefit from lower starting doses and good hygiene education. Those at risk for amputations (prior amputation, peripheral vascular disease neuropathy) may avoid canagliflozin and choose empagliflozin or dapagliflozin. Similarly, patients with osteoporosis or fracture risk should avoid canagliflozin.

Convenience and Combination Therapies

All agents are once daily. Some combinations are available as fixed-dose combinations with metformin, DPP-4 inhibitors, or other drugs. This can reduce pill burden for patients already taking multiple medications. For example, empagliflozin is available with metformin (Synjardy) and linagliptin (Glyxambi).

Cost and Access

Check your insurance formulary. Often, one of the three major agents is preferred. Patient assistance programs require income verification but can reduce copays significantly. If cost is a barrier and ertugliflozin is on a lower tier, it may be a reasonable alternative, though clinical evidence is less robust.

Practical Tips for Starting an SGLT2 Inhibitor

  • Monitor renal function and electrolytes before starting and periodically thereafter (eGFR, potassium).
  • Educate patients about signs of genital infections and how to report them early.
  • Advise patients to maintain adequate fluid intake to minimize dehydration risk.
  • Warn about the rare but serious risk of ketoacidosis; monitor blood ketones if symptoms (nausea, vomiting, breathlessness) occur even if blood glucose is not very high.
  • Consider temporary discontinuation in patients who are hospitalized, undergoing surgery, or experiencing serious illness.
  • For patients on diuretics, consider dose reduction to prevent hypotension and renal impairment.

Conclusion

SGLT2 inhibitors have transformed the management of type 2 diabetes and expanded into cardiorenal protection independently of glycemic status. While canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin share a core mechanism, differences in their approved indications, cardiovascular and renal outcome data, safety profiles, and costs guide individualized prescribing. For most patients with type 2 diabetes and comorbidities, empagliflozin and dapagliflozin are preferred due to their robust evidence base and broader indications. Canagliflozin remains a good option for those with diabetic kidney disease, provided amputation and fracture risks are low. Ertugliflozin may be suitable for some patients, especially if cost or formulary access is an issue.

Ultimately, the decision should be made in collaboration with a healthcare provider who can evaluate the patient's medical history, risk factors, and treatment priorities. Regular follow-up and monitoring are essential to maximize benefits and minimize harms. Do not start or switch SGLT2 inhibitors without first consulting your prescribing clinician.

External Resources for Additional Reading